| 000 | 01628 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517013413.0 | ||
| 264 | 0 | _c20160106 | |
| 008 | 201601s 0 0 eng d | ||
| 022 | _a1096-1186 | ||
| 024 | 7 |
_a10.1016/j.phrs.2015.01.001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiu, Xiangjuan | |
| 245 | 0 | 0 |
_aIrbesartan ameliorates diabetic cardiomyopathy by regulating protein kinase D and ER stress activation in a type 2 diabetes rat model. _h[electronic resource] |
| 260 |
_bPharmacological research _cMar 2015 |
||
| 300 |
_a43-51 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBiphenyl Compounds _xpharmacology |
| 650 | 0 | 4 |
_aCardiotonic Agents _xpharmacology |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Experimental _xdrug therapy |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 |
_aDiabetic Cardiomyopathies _xdrug therapy |
| 650 | 0 | 4 |
_aEndoplasmic Reticulum Stress _xdrug effects |
| 650 | 0 | 4 | _aIrbesartan |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMyocardium _xpathology |
| 650 | 0 | 4 |
_aProtein Kinase C _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aTetrazoles _xpharmacology |
| 700 | 1 | _aXu, Qun | |
| 700 | 1 | _aWang, Xiaomeng | |
| 700 | 1 | _aZhao, Zhuo | |
| 700 | 1 | _aZhang, Liping | |
| 700 | 1 | _aZhong, Ling | |
| 700 | 1 | _aLi, Li | |
| 700 | 1 | _aKang, Weiqiang | |
| 700 | 1 | _aZhang, Yun | |
| 700 | 1 | _aGe, Zhiming | |
| 773 | 0 |
_tPharmacological research _gvol. 93 _gp. 43-51 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.phrs.2015.01.001 _zAvailable from publisher's website |
| 999 |
_c24561872 _d24561872 |
||